These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 8679463)

  • 1. Expression of Bcl-2 in node-negative breast cancer is associated with various prognostic factors, but does not predict response to one course of perioperative chemotherapy.
    van Slooten HJ; Clahsen PC; van Dierendonck JH; Duval C; Pallud C; Mandard AM; Delobelle-Deroide A; van de Velde CJ; van de Vijver MJ
    Br J Cancer; 1996 Jul; 74(1):78-85. PubMed ID: 8679463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. p53 protein accumulation and response to adjuvant chemotherapy in premenopausal women with node-negative early breast cancer.
    Clahsen PC; van de Velde CJ; Duval C; Pallud C; Mandard AM; Delobelle-Deroide A; van den Broek L; Sahmoud TM; van de Vijver MJ
    J Clin Oncol; 1998 Feb; 16(2):470-9. PubMed ID: 9469330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.
    Gasparini G; Barbareschi M; Doglioni C; Palma PD; Mauri FA; Boracchi P; Bevilacqua P; Caffo O; Morelli L; Verderio P
    Clin Cancer Res; 1995 Feb; 1(2):189-98. PubMed ID: 9815973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of bcl-2 expression in invasive breast cancer.
    Hellemans P; van Dam PA; Weyler J; van Oosterom AT; Buytaert P; Van Marck E
    Br J Cancer; 1995 Aug; 72(2):354-60. PubMed ID: 7640218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved local control and disease-free survival after perioperative chemotherapy for early-stage breast cancer. A European Organization for Research and Treatment of Cancer Breast Cancer Cooperative Group Study.
    Clahsen PC; van de Velde CJ; Julien JP; Floiras JL; Delozier T; Mignolet FY; Sahmoud TM
    J Clin Oncol; 1996 Mar; 14(3):745-53. PubMed ID: 8622020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. bcl-2 in normal human breast and carcinoma, association with oestrogen receptor-positive, epidermal growth factor receptor-negative tumours and in situ cancer.
    Leek RD; Kaklamanis L; Pezzella F; Gatter KC; Harris AL
    Br J Cancer; 1994 Jan; 69(1):135-9. PubMed ID: 8286195
    [TBL] [Abstract][Full Text] [Related]  

  • 7. p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients.
    Bottini A; Berruti A; Bersiga A; Brizzi MP; Brunelli A; Gorzegno G; DiMarco B; Aguggini S; Bolsi G; Cirillo F; Filippini L; Betri E; Bertoli G; Alquati P; Dogliotti L
    Clin Cancer Res; 2000 Jul; 6(7):2751-8. PubMed ID: 10914720
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The importance of the histologic grade of invasive breast carcinoma and response to chemotherapy.
    Pinder SE; Murray S; Ellis IO; Trihia H; Elston CW; Gelber RD; Goldhirsch A; Lindtner J; Cortés-Funes H; Simoncini E; Byrne MJ; Golouh R; Rudenstam CM; Castiglione-Gertsch M; Gusterson BA
    Cancer; 1998 Oct; 83(8):1529-39. PubMed ID: 9781946
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant treatment of node-positive breast cancer with cyclophosphamide, doxorubicin, fluorouracil, and vincristine versus cyclophosphamide, methotrexate, and fluorouracil: final report after a 16-year median follow-up duration.
    Misset JL; di Palma M; Delgado M; Plagne R; Chollet P; Fumoleau P; Le Mevel B; Belpomme D; Guerrin J; Fargeot P; Metz R; Ithzaki M; Hill C; Mathé G
    J Clin Oncol; 1996 Apr; 14(4):1136-45. PubMed ID: 8648368
    [TBL] [Abstract][Full Text] [Related]  

  • 10. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer.
    Muss HB; Thor AD; Berry DA; Kute T; Liu ET; Koerner F; Cirrincione CT; Budman DR; Wood WC; Barcos M
    N Engl J Med; 1994 May; 330(18):1260-6. PubMed ID: 7908410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Duration and reintroduction of adjuvant chemotherapy for node-positive premenopausal breast cancer patients.
    International Breast Cancer Study Group
    J Clin Oncol; 1996 Jun; 14(6):1885-94. PubMed ID: 8656257
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of long-term survivors in primary breast cancer by dynamic modelling of tumour response.
    Cameron DA; Gregory WM; Bowman A; Anderson ED; Levack P; Forouhi P; Leonard RC
    Br J Cancer; 2000 Jul; 83(1):98-103. PubMed ID: 10883676
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of persistent node involvement after neoadjuvant chemotherapy in patients with operable breast cancer.
    Pierga JY; Mouret E; Diéras V; Laurence V; Beuzeboc P; Dorval T; Palangié T; Jouve M; Vincent-Salomon A; Scholl S; Extra JM; Asselain B; Pouillart P
    Br J Cancer; 2000 Dec; 83(11):1480-7. PubMed ID: 11076657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of DNA cytometry in 281 premenopausal patients with lymph node negative breast carcinoma randomized in a control trial: multivariate analysis with Ki-67 index, mitotic count, and microvessel density.
    Mandard AM; Denoux Y; Herlin P; Duigou F; van De Vijver MJ; Clahsen PC; van Den Broek L; Sahmoud TM; Henry-Amar M; van De Velde CJ
    Cancer; 2000 Oct; 89(8):1748-57. PubMed ID: 11042570
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic importance of thymidylate synthase expression in early breast cancer.
    Pestalozzi BC; Peterson HF; Gelber RD; Goldhirsch A; Gusterson BA; Trihia H; Lindtner J; Cortés-Funes H; Simmoncini E; Byrne MJ; Golouh R; Rudenstam CM; Castiglione-Gertsch M; Allegra CJ; Johnston PG
    J Clin Oncol; 1997 May; 15(5):1923-31. PubMed ID: 9164203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic role of clinical, pathological and biological characteristics in patients with locally advanced breast cancer.
    Honkoop AH; van Diest PJ; de Jong JS; Linn SC; Giaccone G; Hoekman K; Wagstaff J; Pinedo HM
    Br J Cancer; 1998 Feb; 77(4):621-6. PubMed ID: 9484820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Bcl-2 protein: a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients.
    Silvestrini R; Veneroni S; Daidone MG; Benini E; Boracchi P; Mezzetti M; Di Fronzo G; Rilke F; Veronesi U
    J Natl Cancer Inst; 1994 Apr; 86(7):499-504. PubMed ID: 8133533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High local recurrence risk after breast-conserving therapy in node-negative premenopausal breast cancer patients is greatly reduced by one course of perioperative chemotherapy: A European Organization for Research and Treatment of Cancer Breast Cancer Cooperative Group Study.
    Elkhuizen PH; van Slooten HJ; Clahsen PC; Hermans J; van de Velde CJ; van den Broek LC; van de Vijver MJ
    J Clin Oncol; 2000 Mar; 18(5):1075-83. PubMed ID: 10694560
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumour cell detection in the bone marrow of breast cancer patients at primary therapy: results of a 3-year median follow-up.
    Harbeck N; Untch M; Pache L; Eiermann W
    Br J Cancer; 1994 Mar; 69(3):566-71. PubMed ID: 7510120
    [TBL] [Abstract][Full Text] [Related]  

  • 20. p53 immunohistochemical staining and survival after adjuvant chemotherapy for breast cancer.
    Dublin EA; Miles DW; Rubens RD; Smith P; Barnes DM
    Int J Cancer; 1997 Dec; 74(6):605-8. PubMed ID: 9421356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.